Please try another search
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company’s product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Its products also comprise CS1002, CS2006, CS3005, CS2007, CS2008, CS6001, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Suzhou, China.
Name | Age | Since | Title |
---|---|---|---|
Paul A. Bunn | 78 | 2019 | Member of Scientific Advisory Board |
Hongbin Sun | 48 | 2019 | Independent Non-Executive Director |
- Hu | 60 | 2021 | Non-Executive Director |
Wei Li | 51 | 2015 | Non-Executive Chairman |
Ting Yuk Wu | 69 | 2019 | Independent Non-Executive Director |
Weiping Zou | - | 2019 | Member of Scientific Advisory Board |
Paul Herbert Chew | 72 | 2019 | Independent Non-Executive Director |
Kenneth Walton Hitchner | 64 | 2021 | Non Executive Director |
Xianghong Lin | 54 | 2020 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review